This article provides consensus-based statements from an international panel of bladder cancer experts on the use of active surveillance in non-muscle invasive bladder cancer. Consensus statements cover several aspects of active surveillance, including terminology, eligibility criteria and treatment triggers, providing a framework to guide clinical practice and trial design in this space.
- Roberto Contieri
- Paolo Gontero
- Laura S. Mertens
